Il FTSE MIB segna +0,27%, il FTSE Italia All-Share +0,33%, il FTSE Italia Mid Cap +0,63%, il FTSE Italia STAR +1,29%.
DiaSorin termina la seduta in rialzo nonostante le incertezze mostrate nel durante.
Piazza Affari in progresso. BTP stabili e spread in miglioramento. Il rendimento del decennale segna 0,56% (chiusura precedente a 0,56%), lo spread sul Bund 116 bp (da 118) (dati MTS).
Debole DiaSorin -0,9% penalizzata dall'ok della FDA americana all'utilizzo e quini alla distribuzione immediata del vaccino Pfizer-BioNTech.
Piazza Affari tonica in avvio con ok FDA a vaccino Pfizer e trattative Brexit. BTP e spread stabili. Il rendimento del decennale segna 0,56% (chiusura precedente a 0,56%), lo spread sul Bund 118 bp (da 118) (dati MTS).
La big pharma anglo-svedese, mentre lavora al suo vaccino contro il coronavirus, scommette 39 miliardi sulla biotech di Boston e sulle malattie rare.
U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Olderdi Business Wire
Recommendation follows yesterday’s FDA authorization for emergency use of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2), to address the crisis
Based on urgent need, Committee recommends Pfizer-BioNTech COVID-19 vaccine for persons 16 years of age and older under U.S. FDA’s Emergency Use Authorization; earlier this month, the Committee recommended a phased allocation of vaccine distribution with Phase 1a to prioritize health care personnel treating patients, and residents in nursing homes and other long-term care facilities
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19di Business Wire
U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately
Pfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021
In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021
Historic science-driven efforts will seek to help bring an end to the most devastating pandemic in a century
Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021
Pfizer ha annunciato l'approvazione da parte del board dell'aumento della cedola trimestrale a 39 centesimi dai 38 centesimi dello scorso anno.
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.di Business Wire
FDA expected to make a decision on Emergency Use Authorization in the coming days
Positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data
If authorized, BNT162b2 would be the first COVID-19 vaccine available in the U.S.
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicinedi Business Wire
Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose
Vaccine efficacy observed in the overall study population was also generally consistent across subgroups defined by age, gender, race, ethnicity, baseline body mass index (BMI), or presence of other underlying co-morbidities
Partial protection from the vaccine candidate appears to begin as early as 12 days after the first dose
These data were included in the requests for regulatory authorization submitted to regulatory agencies across the globe, including the U.S. Food and Drug Administration and the European Medicines Agency
Molti analisti sembrano essere concordi nel giudicare l'Asia, Giappone escluso, come l'area nella quale sarà più facile fare fruttare i propri investimenti nel 2021.
Partenza al rialzo per il future Eurostoxx 50.
La Borsa di New York ha chiuso la seduta in rialzo sostenuta dalle speranze per una rapida vaccinazione di massa contro il Covid-19.
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Olderdi Business Wire
If approved, the vaccine will help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia
Pfizer guadagna il 2% al Nyse.